Feb 27 |
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
|
Feb 14 |
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
|
Feb 13 |
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
|
Feb 8 |
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
|
Feb 7 |
Zentalis Pharmaceuticals: Azenosertib Continues To Impress
|
Feb 6 |
Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
|
Feb 5 |
Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
|
Jan 25 |
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
|
Jan 8 |
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
|
Dec 27 |
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
|